|
Talmadge E. King, Jr., MD is the recipient of the Julius R. Krevans Distinguished Professorship in Internal Medicine award and Chair of the Department of Medicine at the University of California, San Francisco (UCSF). Dr. King is a graduate of Gustavus Adolphus College and received his medical degree from Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals, Atlanta, Georgia, and a pulmonary fellowship at the University of Colorado Health Sciences Center, Denver. He held a professorship in medicine at the University of Colorado Health Sciences Center, and was a senior faculty member at the National Jewish Medical and Research Center. He is a member of the American Academy of Arts and Sciences, Institute of Medicine of the National Academy of Sciences, Association of American Physicians, American Clinical and Climatological Association, Fleischner Society, and is a master of the American College of Physicians and a fellow the American College of Chest Physicians. Dr. King is an active member of a number of professional societies and is a past President of the American Thoracic Society (ATS). Dr. King serves on the National Heart, Lung, and Blood Advisory Council; National Committee for Quality Assurance; and is Secretary/Treasurer of Board of the American Board of Internal Medicine. He has served on the Lung Biology and Pathology Study Section of the NIH; American Board of Medical Specialties, Pulmonary and Allergy Drugs Advisory Committee Center for Drug Evaluation & Research of the FDA; NIH Advisory Board for Clinical Research (ABCR), and the Board of Extramural Advisors of the National Heart Lung and Blood Institute. He was a member of the editorial boards of American Journal of Respiratory and Critical Care Medicine, Annals of Internal Medicine, THORAX, and UpToDate™ In Pulmonary and Critical Care. He has been an editorial consultant for more than a dozen journals. For 9 years he was a member of the Board of Trustees of Gustavus Adolphus College. Dr. King has won numerous awards, among them election to the Colorado Pulmonary Hall of Fame and the Trudeau Medal from the ATS. Dr. King has been listed on several of the "best doctors" list in America for more than a decade (including "Best Doctors in America" and "America's Top Doctors"). His bibliography comprises >300 publications including peer-reviewed journal articles; book chapters, critical reviews, editorials, and monographs. He has co-authored 12 books including the acclaimed reference book "Interstitial Lung Disease", now in its 5th edition. He is a co-editor of Murray & Nadel’s Textbook of Respiratory Medicine (5th ed.). He co-edited "Medical Management of Vulnerable & Underserved Patients: Principles, Practice, Population," the only reference currently available that focuses on the treatment of patients living with chronic diseases in poor and minority populations.
Our overall focus has been on understanding the pathogenesis, diagnosis and management of inflammatory and immunology lung injury. In particular, we are improving our understanding of the immunopathogenesis of idiopathic pulmonary fibrosis. Another aim is to develop and evaluate methods that can serially identify the presence and extent of disease activity in these patients. With support from the Department of Medicine, we have developed an Interstitial Lung Disease Center of Excellence.
Dr. King’s bibliography comprises hundreds of publications including peer-reviewed journal articles; book chapters, review, editorials; books, monographs, and abstracts. Please visit PubMed for entire list.
Some recent publications include:
Selman, M. King TE, Jr, Pardo A. Idiopathic Pulmonary Fibrosis: Prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001; 134:136-151 .[Abstract/Free Full Text]
King TE, Jr. (Chair), Costabel U, et al. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. This is a joint statement from the American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J. Respir Crit Care Med 2000; 161: 646-664.
Schwarz, MI, King TE Jr. (eds) Interstitial Lung Disease (5th Edition). People's Medical Publishing House. Beijing, China (2011)
Travis WD, Hunninghake G, King TE, Jr, Lynch DA, Colby TV, Galvin JR, Brown KK, Chung, MP, Cordier J-F, duBois RM, Flaherty KR, Franks TJ, Hansell DM, Hartman TE, Kazerooni EA, Kim DS, Kitaichi M, Koyama T, Martinez FJ, Nagai S, Midthun DE, Müller NL, Nicholson AG, Raghu G, Selman M, Wells A. Idiopathic Nonspecific Interstitial Pneumonia: Report of an ATS Workshop. Am. J. Respir. Crit. Care Med. 2008:177:1338-1347
King TE, Jr., Wheeler M, Bindman A, Fernandez A, Grumbach K, Schillinger D, Villela T. Medical Management of Vulnerable & Underserved Patients: Principles, Practice, & Populations. McGraw-Hill Com., New York, NY, pp. 408; 2007. ISBN: 0071443312 DOI: 10.1036/0071443312 [Abstract/Free Full Text]
King TE Jr, Behr J, Brown KK, du Bois R, Lancaster L, de Andrade JA, Stähler G, Leconte I, Roux S, Raghu R. Bosentan for the treatment of idiopathic pulmonary fibrosis: the randomized, double-blind, placebo-controlled BUILD 1 study. Am. J. Respir. Crit. Care Med. 2008; 177:75–81. (Prepublished online September 27, 2007) PMID: 17901413
http://ajrccm.atsjournals.org/cgi/content/short/177/1/75
Kinder BW, Schwarz MI, Brown KK, Ix JH, Kervitsky D, King TE Jr. Baseline Bronchoalveolar Lavage Neutrophilia predicts Early Survival in Idiopathic Pulmonary Fibrosis. CHEST 2008; 133;226-232; (Prepublished online December 10, 2007) PMID: 18071016
http://chestjournal.chestpubs.org/content/133/1/226.full
Kinder BW, Brown KK, McCormack FX, Ix JH, Kervitsky D, Schwarz MI, King TE Jr. Baseline serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. CHEST 2009; 135:1557-63 PMID: 19255294
Kim E, Collard HR, King TE Jr. Rheumatoid Arthritis-Associated Interstitial Lung Disease: The Relevance of Histopathologic and Radiographic Pattern. Chest 2009;136: 1397-1405
Lee JS, Collard HR, Raghu G, Sweet MP, Hays SR, Campos GM, Golden JA, King TE Jr Does Chronic Microaspiration Cause Idiopathic Pulmonary Fibrosis? Am J Med 2010; 123: 304-311. PMID: 20362747 http://www.ncbi.nlm.nih.gov/pubmed/20362747
Ley B, Collard HR, King TE, Jr. Clinical Course and Prediction of Survival in Idiopathic Pulmonary Fibrosis Am. J. Respir. Crit. Care Med. Published online on October 8, 2010 as doi:10.1164/rccm.201006-0894CI
King TE Jr, Albera C, Bradford WZ, Costabel U, Noble PW, Szwarcberg J, Thomeer M Valeyre D, du Bois RM, for the INSPIRE Study Group. The Effect of Interferon Gamma-1b on Survival in Patients with Idiopathic Pulmonary Fibrosis: A Multinational Randomized Placebo-Controlled Trial. Lancet 2009; 374:222-228
King TE Jr, Pardo P, Selman M. Idiopathic pulmonary fibrosis. The Lancet. 2011. (Early Online Publication, 28 June 2011; doi:10.1016/S0140-6736(11)60052-4) |
